FDA approves Lilly's diabetes treatment; Watson locates R&D center in NJ

@FierceBiotech: Lilly's losses put pressure on key Alzheimer's program. How will Lechleiter's R&D strategy fare? Article | Follow @FierceBiotech

@JohnCFierce: Ketamine ("Special K") for depression? Being studied in IV form, also new pill. Story | Follow @JohnCFierce

@RyanMFierce: Lilly ($LLY) gained an FDA nod for a linagliptin-metformin combo pill for diabetes partnered with Boehringer. News | Follow @RyanMFierce

@MarkHFierce: A 2,200 year old mummy had prostate cancer. Researchers say the finding proves cancer is caused by genetics. More | Follow @MarkHFierce

> Generic drugmaker Watson Pharmaceuticals ($WPI) aims to house its global R&D center in North Brunswick, NJ. Article

> The FDA has stamped an approval on Jentadueto, Eli Lilly's ($LLY) pill that combines two drugs and is partnered with Boehringer Ingelheim. Report

> NPS Pharmaceuticals ($NPSP) said that the FDA has accepted in app for approval of the drug Gattex for treating short bowel syndrome. Release

Pharma News

@FiercePharma: Two chairmen replaced as J&J takes another crack at overhauling McNeil, WSJ reports. Article | Follow @FiercePharma

> Turkish drugmaker wooed by GSK, Pfizer, Bloomberg says. More

> WSJ: Another executive shake-up at J&J's McNeil unit. Article

> Pfizer, Lilly earnings drop on new generic rivals. News

> Depressed study subjects spell relief with Special K. Story

Research News

> New target could be key to beating back methamphetamine addiction. More

> Meet cancer's latest enemy: grape seed extract. Article

> Team finds 2 mutations that cause pediatric brain cancer. More

> Mutated melanoma receptor heightens diabetes risk. Story

> Nearly $11M to fund new Joslin Diabetes Center research facility. Item

Pharma Manufacturing News

> Teva's Cephalon recalls leukemia drug over fragments in vial. News

> Pfizer workers at manufacturing hub sue over whiplashed retirement plans. Article

> Company whistleblower program part of Ranbaxy consent decree. News

> Gutted J&J consumer healthcare plant another year from reopening. Story

> Medicines Company, APP settlement includes manufacturing agreement. Item

And Finally... GlaxoSmithKline CEO Andrew Witty shared his thoughts with the U.K.'s Guardian about the Bill Gates-backed initiative involving 13 pharma groups to combat deadly tropical diseases. Item

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.